Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247593 | 0.89 | GPR35 (0.49) | ACHEMEN1KMT2AGPR35ALDH1A1 | |
| SCHEMBL4248701 | 0.87 | GPR35 (0.48) | ACHEMEN1KMT2AGPR35ALDH1A1 | |
| SCHEMBL4994397 | 0.86 | GPR35 (0.48) | MEN1KMT2AGPR35ALDH1A1KDM4E | |
| SCHEMBL4251118 | 0.85 | GPR35 (0.47) | ACHEMEN1KMT2AGPR35ALDH1A1 | |
| SCHEMBL4250257 | 0.85 | GPR35 (0.49) | ACHEMEN1KMT2AGPR35ALDH1A1 | |
| SCHEMBL4249890 | 0.84 | GPR35 (0.48) | ACHEMEN1KMT2AGPR35ALDH1A1 | |
| SCHEMBL4254261 | 0.84 | GPR35 (0.46) | ACHEMEN1KMT2AGPR35KDM4E | |
| SCHEMBL4989412 | 0.83 | GPR35 (0.46) | MEN1KMT2AGPR35ALDH1A1KDM4E | |
| SCHEMBL932185 | 0.79 | PRMT1 (0.57) | PRMT1ALDH1A1LMNA | |
| SCHEMBL932222 | 0.79 | PRMT1 (0.59) | PRMT1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | ACHE 426/4885PRMT1 1611/4885MEN1 214/4885 |
| US-20090170851-A1 | Chroman Compounds | CYP3A43, CYP2C9, CYP2C8 | ACHE 462/4885PRMT1 1421/4885MEN1 268/4885 |
| US-20070185107-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | ACHE 462/4885PRMT1 1421/4885MEN1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.